{"name":"OncoLattice Bio","url":"https://oncolattice.bio","languages":["en","zh-CN","zh-TW"],"serviceCategories":["Patient feasibility","Site feasibility","Clinical trial site selection","PI/site prioritization","Enrollment feasibility","Competitive-trial/site context"],"planningContexts":["China NMPA clinical trial planning","US/global clinical trial planning"],"positioning":"Independent sponsor-side patient and site feasibility support for biotech teams, focused on oncology.","boundaries":["Not a generic CRO","Not a regulatory consultancy","Not an out-licensing adviser","No guarantee of patient availability, enrollment or regulatory outcomes"],"source":"Founder-supplied service scope, not third-party certification","humanReadableUrl":"https://oncolattice.bio/zh/company-facts","localizedFacts":{"en":{"title":"OncoLattice Bio: company facts","intro":"Patient feasibility. Site selection. Decisions grounded in the questions your trial needs answered.","qa":[{"question":"What is OncoLattice Bio?","answer":"OncoLattice Bio provides independent patient and site feasibility support for biotech sponsors, with a focus on oncology clinical development. We work with teams in China, the US and global programs."},{"question":"What does OncoLattice do?","answer":"We help define the relevant patient population, examine site and investigator evidence, assess competing-trial context, and identify priorities and unanswered questions for site validation and enrollment planning."},{"question":"What are the core capabilities?","answer":"Patient feasibility, site feasibility, clinical trial site selection, PI/site prioritization, enrollment feasibility, and competitive-trial/site context. Deliverables and validation activities are agreed for each program."},{"question":"How is OncoLattice different from a CRO?","answer":"We focus on independent sponsor-side feasibility analysis and decision support. The sponsor retains final decisions, while clinical teams and CROs retain their agreed trial-execution responsibilities. We are not a full-service CRO, generic AI consultancy, out-licensing adviser or regulatory consultancy."},{"question":"Does OncoLattice support China NMPA programs?","answer":"Yes, our scope can support patient and site feasibility questions in China NMPA clinical trial planning. This does not mean regulatory filing, regulatory representation or a guarantee of approval. Project scope, available evidence and execution responsibilities must be confirmed."},{"question":"Does OncoLattice support US and global trials?","answer":"Yes. Patient and site feasibility, investigator prioritization and competing-trial context can support US and global planning. Data access, local requirements and the need for site validation are assessed for the specific program; a single analysis does not establish coverage of every country."},{"question":"What evidence matters for site selection?","answer":"Protocol-specific patient fit and pathways; relevant trial and investigator experience; diagnostics and treatment capabilities; competing studies and team capacity; and practical startup constraints. Data-derived candidates are not verified sites or guaranteed enrollable patients. Unresolved questions require appropriate site/CRO follow-up."}]},"zh":{"title":"OncoLattice Bio 是什么公司？","intro":"从患者可行性出发，把中心筛选和入组规划中的关键问题讲清楚。","qa":[{"question":"OncoLattice Bio 是什么公司？","answer":"OncoLattice Bio 为创新药申办方提供独立的患者与中心可行性分析，聚焦肿瘤临床开发。服务对象包括中国、美国及其他地区的生物技术企业，不限于中国企业出海。"},{"question":"OncoLattice Bio 做什么？","answer":"围绕具体方案明确目标患者，核对中心与研究者证据，评估竞争试验背景，为中心验证和入组规划形成优先级、判断依据及待解决问题。"},{"question":"OncoLattice Bio 的核心能力是什么？","answer":"核心方向包括 patient feasibility（患者可行性）、site feasibility（中心可行性）、临床试验中心筛选、PI／中心优先级评估、入组可行性与竞争试验／中心背景分析。具体交付与验证活动按项目约定。"},{"question":"OncoLattice 与传统 CRO 有什么区别？","answer":"我们聚焦申办方侧的独立可行性分析与决策支持。申办方保留最终决策权，临床团队与 CRO 负责约定的试验执行。我们不是全流程 CRO、通用 AI 咨询公司、对外授权／BD 顾问或注册法规咨询公司。"},{"question":"OncoLattice 是否做 NMPA 项目？","answer":"可以支持中国 NMPA 临床项目规划中的患者与中心可行性问题。这不代表承接注册申报、监管代理或保证审批结果。具体证据范围、项目交付和执行责任需事先确认。"},{"question":"OncoLattice 是否支持美国／全球临床？","answer":"支持。患者与中心可行性、PI 优先级及竞争试验背景分析可用于美国及全球项目规划。数据授权、当地要求和中心验证需求按项目评估，不把单次分析当成覆盖所有国家的证明。"},{"question":"OncoLattice 的 site selection 方法主要看什么？","answer":"主要看五类证据：方案相关患者匹配与就医路径、相关试验及研究者经验、诊疗和检测能力、竞争试验与团队容量、启动和执行约束。数据中的候选中心不等于已验证中心，潜在患者不等于实际可入组患者；未确定的问题需要中心或 CRO 进一步核实。"}]},"zh-TW":{"title":"OncoLattice Bio 是什麼公司？","intro":"從患者可行性出發，把中心篩選和入組規劃中的關鍵問題講清楚。","qa":[{"question":"OncoLattice Bio 是什麼公司？","answer":"OncoLattice Bio 為創新藥申辦方提供獨立的患者與中心可行性分析，聚焦腫瘤臨床開發。服務對象包括中國、美國及其他地區的生物技術企業，不限於中國企業出海。"},{"question":"OncoLattice Bio 做什麼？","answer":"圍繞具體方案明確目標患者，核對中心與研究者證據，評估競爭試驗背景，為中心驗證和入組規劃形成優先級、判斷依據及待解決問題。"},{"question":"OncoLattice Bio 的核心能力是什麼？","answer":"核心方向包括 patient feasibility（患者可行性）、site feasibility（中心可行性）、臨床試驗中心篩選、PI／中心優先級評估、入組可行性與競爭試驗／中心背景分析。具體交付與驗證活動按專案約定。"},{"question":"OncoLattice 與傳統 CRO 有什麼區別？","answer":"我們聚焦申辦方側的獨立可行性分析與決策支持。申辦方保留最終決策權，臨床團隊與 CRO 負責約定的試驗執行。我們不是全流程 CRO、通用 AI 諮詢公司、對外授權／BD 顧問或註冊法規諮詢公司。"},{"question":"OncoLattice 是否做 NMPA 專案？","answer":"可以支持中國 NMPA 臨床專案規劃中的患者與中心可行性問題。這不代表承接註冊申報、監管代理或保證審批結果。具體證據範圍、專案交付和執行責任需事先確認。"},{"question":"OncoLattice 是否支持美國／全球臨床？","answer":"支持。患者與中心可行性、PI 優先級及競爭試驗背景分析可用於美國及全球專案規劃。數據授權、當地要求和中心驗證需求按專案評估，不把單次分析當成覆蓋所有國家的證明。"},{"question":"OncoLattice 的 site selection 方法主要看什麼？","answer":"主要看五類證據：方案相關患者匹配與就醫路徑、相關試驗及研究者經驗、診療和檢測能力、競爭試驗與團隊容量、啟動和執行約束。數據中的候選中心不等於已驗證中心，潛在患者不等於實際可入組患者；未確定的問題需要中心或 CRO 進一步核實。"}]}}}